Time to Buy Beat-Down 10x Genomics Inc. (TXG) Stock? Here is the INSIGHT

10x Genomics Inc. (TXG) is priced at $160.93 after the most recent trading session. At the very opening of the session, the stock price was $156.15 and reached a high price of $162.39, prior to closing the session it reached the value of $157.04. The stock touched a low price of $156.15.

Recently in News on October 13, 2020, 10x Genomics to Report Third Quarter Financial Results on November 10, 2020. 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2020 after market close on Tuesday, November 10, 2020. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook. You can read further details here

10x Genomics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $162.39 on 10/13/20, with the lowest value was $48.78 for the same time period, recorded on 03/23/20.

10x Genomics Inc. (TXG) full year performance was 220.19%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, 10x Genomics Inc. shares are logging 1.20% during the 52-week period from high price, and 231.80% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $48.50 and $159.02.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1012643 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the 10x Genomics Inc. (TXG) recorded performance in the market was 111.06%, having the revenues showcasing 76.98% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 16.51B, as it employees total of 713 workers.

The Analysts eye on 10x Genomics Inc. (TXG)

During the last month, 8 analysts gave the 10x Genomics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 102.74, with a change in the price was noted +84.93. In a similar fashion, 10x Genomics Inc. posted a movement of +111.75% for the period of last 100 days, recording 840,475 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for TXG is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical rundown of 10x Genomics Inc. (TXG)

Raw Stochastic average of 10x Genomics Inc. in the period of last 50 days is set at 97.91%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 96.89%. In the last 20 days, the company’s Stochastic %K was 97.01% and its Stochastic %D was recorded 97.85%.

Considering, the past performance of 10x Genomics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 111.06%. Additionally, trading for the stock in the period of the last six months notably improved by 140.91%, alongside a boost of 220.19% for the period of the last 12 months. The shares increased approximately by 17.66% in the 7-day charts and went down by 33.10% in the period of the last 30 days. Common stock shares were driven by 76.98% during last recorded quarter.